Protocol Ledger

NCT03783923 · Phase III · TERMINATED

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Interventional Phase III clinical trial protocol NCT03783923 sponsored by PTC Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-31 Enrollment: 11 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03783923
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)11 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03783923
Protocol FieldVerified Registry Value
NCT IdentifierNCT03783923
Consolidated Lead SponsorPTC Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment11 participants (ACTUAL)
Registered Start Date2019-10-31
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI